Colorectal cancer in 2017

Practice-changing updates in the adjuvant and metastatic setting

2017 has been full of new discoveries that will influence the treatment of colorectal cancer. In the adjuvant setting, 3 months of chemotherapy might now be considered a new standard of care. Various other new treatments and promising biomarkers have also become available that will improve survival outcomes and the quality of life of many patients with metastatic disease.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Shi, Q. et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 versus 6 months) for patients (pts) with stage III colon cancer (CC): the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration [abstract]. J. Clin. Oncol. 35 (Suppl.), LBA1 (2017).

    Article  Google Scholar 

  2. 2

    Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3

    Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4

    Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5

    Arnold, D. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 28, 1713–1729 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6

    Tejpar, S. et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the crystal and fire-3 trials. JAMA Oncol. 3, 194–201 (2017).

    Article  PubMed  Google Scholar 

  7. 7

    Aljehani, M. A. et al. Association of primary tumor site with mortality in patients receiving bevacizumab and cetuximab for metastatic colorectal cancer. JAMA Surg. http://dx.doi.org/10.1001/jamasurg.2017.3466 (2017).

  8. 8

    Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9

    Lenz, H.-J. et al. Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance) [abstract]. J. Clin. Oncol. 35 (Suppl.), 3511 (2017).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Heinz-Josef Lenz.

Ethics declarations

Competing interests

A.P. declares no competing interests. H.-J.L. has received financial support for clinical trials from Merck Serono and Roche, and honoraria for advisory board membership and lectures from Bayer, Boehringer Ingelheim, Genentech, Merck Serono and Roche.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Puccini, A., Lenz, H. Practice-changing updates in the adjuvant and metastatic setting. Nat Rev Clin Oncol 15, 77–78 (2018). https://doi.org/10.1038/nrclinonc.2017.185

Download citation

Further reading

Search

Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing